Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Active, not recruiting · NCT05397496 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05397496 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Ctr | New York | United States | 9 |
| Oregon Health Sciences University | Portland | United States | 33 |
| The University of Kansas Clinical Research Ctr | Fairway | United States | 1 |
| University of Chicago Medical Center | Chicago | United States | 152 |
| University of Miami | Miami | United States | 327 |